Stock Updates

How has Alexion Pharmaceuticals, Inc.:(NASDAQ:ALXN) performed recently?

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is a large market cap stock with a market cap of 29560.37. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 181.62, a forward P/E of 20.01 and EPS of 0.72. At a stock price of 128.46 (-1.49%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 5.10%, more recently this last year it has grown by -79.50%. The next year growth is going to be about 29.13% and more long-term 19.20% after five years. EPS growth quarter over quarter is -10.10%. Sales growth for the past five years have been 36.90% and sales growth quarter over quarter is 16.80%.

For performance, Alexion Pharmaceuticals, Inc. the past week has seen a gain of 2.44%. For the last month performance for Alexion Pharmaceuticals, Inc. is 13.45%. While the last quarter is -8.51% and half year, -10.45%. Finally for the year, performance is -34.39%.

The 52-week high for Alexion Pharmaceuticals, Inc., is at -37.43%, and for the 52-week low it comes to a value of 16.19%. The 20-day simple moving average is -2.18% and -15.19% for the 200-day simple moving average.

Volatility for the week is at 2.78%, and for the month it is 2.65%. Alexion Pharmaceuticals, Inc., has a target price of 179.72.

In terms of debt, long term debt/equity is 0.4, and for total debt/equity Alexion Pharmaceuticals, Inc. has 0.4. The gross margin is 91.80%, while operating margin is 22.10%, the profit margin is 5.40%. The current ratio is 3.5 and the quick ratio is 3.

Insider ownership is at 0.60%, with instituitional ownership at 98.80%. Alexion Pharmaceuticals, Inc. has a payout ratio of 0.00%. With the total shares outstanding coming to 226.69. The shares float is 223.19, with the float short at 2.12%, with short ratio coming to 2.43.

In terms of returns, the return on assets see Alexion Pharmaceuticals, Inc., get 1.10%, with its returns on investment at 1.60%. Return on equity is 1.80%. So will the investors see the target price of 179.72, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Tony Dabbs

Leave a Comment